This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer
Audrey Beaufils, et al.. Journal of Clinical Oncology, 2026.
DOI: 10.1200/JCO-26-00327
-
Leica Biosystems Enables Faster Cancer Diagnoses Through Multiple Digital Pathology FDA Clearances, Including Industry-First AI-Assisted Quality Control Software
-
Doctors vs. Algorithms: Physicians, too, struggle to learn from evidence that contradicts AI suggestions
Aranzazu Vinas, et al.. PLOS Digital Health, 2026.
DOI: 10.1371/journal.pdig.0001490
Weekly News Brief: August 10–14, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of August 10–14, 2026.
This week’s brief covers an AI histology-based biomarker guiding adjuvant chemotherapy choice in pancreatic cancer, the FDA cleared new digital pathology scanners and quality control software, and a study found physicians followed incorrect AI patient labels despite contradictory feedback.
To learn more about a histology-based AI biomarker, read "AI Biomarker Directs Adjuvant Chemotherapy Choice in Pancreatic Ductal Adenocarcinoma," or see the source report in the Journal of Clinical Oncology.
For more information on digital pathology clearances, read "New FDA-Cleared Scanners and Quality Control Software Aim to Scale Digital Pathology," or see the press release.
To learn more about doctors vs algorithms, read "Experimental Study Finds Physicians Susceptible to Causal Illusions From AI-Generated Patient Classifications," or see the source report in PLOS Digital Health.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.